Drug intelligence / Profile preview

thrombin receptor-activating peptide 6

Development stage
Unknown
Lead developer
University of Cambridge
Modality
Peptides
Administration
Intravenous
01

Overview

TRAP-6 (Thrombin Receptor Activating Peptide 6) is a synthetic hexapeptide with the amino acid sequence Ser-Phe-Leu-Leu-Arg-Asn (SFLLRN). It functions as a potent and selective agonist for the Proteinase-Activated Receptor 1 (PAR1), a G protein-coupled receptor that is typically activated by thrombin. TRAP-6 works by mimicking the new N-terminal "tethered ligand" that is exposed when thrombin cleaves the PAR1 receptor. Because it does not require enzymatic cleavage to activate the receptor, it is a valuable pharmacological tool in research for investigating PAR1-mediated pathways in platelet aggregation, inflammation, and pain signaling. In clinical diagnostics, TRAP-6 is utilized in ex vivo platelet function assays, such as the Multiplate TRAPtest, to assess the responsiveness of the PAR1 pathway. Recent research has also highlighted its role in mediating visceral pain and nociceptor activation in models of colitis.

Other names
SFLLRN peptideThrombin receptor agonist peptidePAR1 agonist peptidePAR-1 agonist peptidePAR 1 agonist peptide
02

Targets

PAR2 (Protease-activated receptor 2)F2R (Protease-activated receptor 1)

Beyond the preview

Go deeper on thrombin receptor-activating peptide 6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on thrombin receptor-activating peptide 6.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call